Verve Therapeutics, Inc.

Beam Therapeutics sees BEAM-302 as having potential for eventual accelerated approval from the US Food and Drug Administration in alpha-1 antitrypsin deficiency (AATD) after announcing positive early

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

Verve Therapeutics’ loss of Vertex as a partner has generated headlines this week but the gene-editing company’s real make-or-break moment could be just around the corner. The in vivo base editing b

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding